---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-130283"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:23:52.535634+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# OnKure raises $150M in PIPE; plans IND filings for PI3Kα pan-mutant inhibitors in H1 2027

## Summary
- Private placement of ~26.7M shares at $4.15 and ~9.4M pre-funded warrants; gross proceeds ~$150M.
- Proceeds to fund development of PI3Kα pan-mutant inhibitors OKI-345 (breast cancer) and OKI-355 (vascular anomalies).
- IND submissions for OKI-345 and OKI-355 planned for H1 2027; no further independent development of OKI-219.
- Dr. Liam Ratcliffe appointed to board effective at closing, designated by lead investor AI Biotechnology.
- Officers/directors and company subject to 180-day lock-up (or until registration effective) on share issuance/sales.

## SEC filing metadata
- accession: 0001193125-26-130283
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000119312526130283/0001193125-26-130283-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000119312526130283/d910791d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-130283
- JSON: https://secwatch.observer/filing/0001193125-26-130283.json
- Plain text: https://secwatch.observer/filing/0001193125-26-130283.txt

## Key facts
- Material Agreements
  OnKure Therapeutics, Inc. entered into Purchase Agreement with certain institutional accredited investors valued at approximately $150.0 million (effective 2026-03-27).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional accredited investors
  - Value: approximately $150.0 million
  - Effective: 2026-03-27
  source text: On March 27, 2026, OnKure Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement (i) 26,713,636 shares (the “Shares”) of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), at a purchase price of $4.15 per Share, and (ii) pre-funded warrants (the “Pre-Funded Warrants” and together with the Shares, the “Securities”) to purchase 9,430,959 shares of Common Stock (the “Warrant Shares”), at a purchase price of $4.1499 per underlying Warrant Share (the “Private Placement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000119312526130283/0001193125-26-130283-index.htm
- Material Agreements
  OnKure Therapeutics, Inc. entered into Registration Rights Agreement with the Company and the Investors (effective 2026-03-27).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the Company and the Investors
  - Effective: 2026-03-27
  source text: the Company and the Investors also entered into a Registration Rights Agreement, dated March 27, 2026 (the “Registration Rights Agreement”), providing for the registration for resale of the Shares and the Warrant Shares, pursuant to a registration statement (the “Registration Statement”) to be filed with the SEC within 30 days after the Closing Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000119312526130283/0001193125-26-130283-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.